Effect of the bacillus of Calmette-Guérin, Propionibacterium acnes and avridine as immunomodulators in antirabies vaccination of mice using the Fuenzalida-Palacios mouse brain vaccine

Megid, Jane; Peraçolli, M.T.S; Curi, P. R.; Zanetti, Carlos Roberto; Cabrera, Wafa Hanna Koury; Vassão, Ruth Camargo; Ito, F. H.

doi:10.1016/s0264-410x(98)00465-4

Cited by 5 publications

(3 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Immune enhancement by Eqstim R has been demonstrated by a number of immune markers including the amplification of interferon production, and increased macrophage and lymphocyte function [15]. Higher levels of IFN-γ production have been observed in rabies vaccinated mice when given inactivated P. acnes compared to mice without P. acnes or other potential immunstimulants including avridine and BCG [25]. The mechanism of action of P. acnes appears to be both on the macrophages and natural killer cells [25,26].…”

Section: Introductionmentioning

confidence: 99%

“…Higher levels of IFN-γ production have been observed in rabies vaccinated mice when given inactivated P. acnes compared to mice without P. acnes or other potential immunstimulants including avridine and BCG [25]. The mechanism of action of P. acnes appears to be both on the macrophages and natural killer cells [25,26]. Similar immune stimulation is required for immunity to tuberculosis, and leads to a potential role of Propionibacterium sp.…”

Section: Introductionmentioning

confidence: 99%

“…as an adjuvant for such a vaccine. P. acnes is however, a potential pathogen, and efficacy to date has been demonstrated by inactivated organism given via either the intra-venous or intra-peritoneal route [15,25,26].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

The efficacy of Propionibacterium jensenii 702 to stimulate a cell-mediated response to orally administered soluble Mycobacterium tuberculosis antigens using a mouse model

Adams

Lean

Hitchick

et al. 2005

Lait

View full text Add to dashboard Cite

-Mucosal vaccination using adjuvant protein vaccines may offer a novel approach for tuberculosis. To date, however, development of such a vaccine has been considered unlikely due to the inability to identify a safe adjuvant that stimulates an appropriate immune response. This study was undertaken to determine the potential of a dairy propionibacteria, P. jensenii strain 702 (PJ702), to act as an adjuvant when co-administered orally with soluble tuberculosis protein to mice. The efficacy of the PJ702 to act as an adjuvant was assessed by comparison with cholera toxin. C57 mice were orally immunized with Mycobacterium tuberculosis short-term culture filtrate protein (STCF) (200 µg) with either PJ702 (10 8 cfu) or cholera toxin (10 µg) in a total volume of 100 µL. A control group was given PJ702 10 8 cfu alone. Each mouse (eight per group) was vaccinated weekly over a 21-day period. At day 25 the mice were sacrificed, spleens were collected and lymphocyte cultures prepared. After stimulation with STCF (2.5 µg), cell proliferation was measured by 3 H thymidine uptake, and the cytokines, IL-4 and IFN-γ , by ELISA. A significantly higher T-cell proliferation was observed for the group given the vaccine containing PJ702, compared to both the control group and the group given the vaccine containing cholera toxin (P < 0.05). The predominant cytokine produced from all groups was IFN-γ . These results indicate potential for future development of an oral tuberculosis vaccine, and also identify PJ702 as a potential living vaccine vector that could be applied to a number of mucosally transmitted diseases. PJ702 (10 8 ufc) ou avec la toxine cholérique (10 µg), dans un volume total de 100 µL. Un groupe témoin a reçu PJ702 seul (10 8 ufc). Chaque souris (8 par groupe) a été vaccinée hebdomadairement sur une période de 21 jours. Le 25 e jour, les souris ont été sacrifiées, la rate prélevée et les lymphocytes mis en culture. Après stimulation par STCF (2,5 µg), la prolifération cellulaire a été évaluée par mesure de l'incorporation de la thymidine 3 H ; la production des cytokines, IL-4 et IFN-γ , a été évalué par ELISA. Une prolifération des cellules T significativement plus élevée a été observée dans le groupe recevant le vaccin contenant PJ702, par rapport au groupe témoin, ou au groupe recevant le vaccin contenant la toxine cholérique (P < 0,05). La cytokine majoritairement produite dans tous les groupes était IFN-γ . Ces résultats montrent le potentiel de développement d'une stratégie de vaccination orale contre la tuberculose. PJ702 est identifié comme un vecteur potentiel pour délivrer des vaccins vivants, applicable aux différents types de maladies d'origine mucosale.Propionibacterium / tuberculose / vaccin / réponse immunitaire / adjuvant

show abstract

Section: Introductionmentioning

confidence: 99%